Format

Send to

Choose Destination
See comment in PubMed Commons below
Korean J Gastroenterol. 2011 Apr;57(4):207-12. doi: 10.4166/2011.57.4.207.

[Second line chemotherapy for pancreatic cancer].

[Article in Korean]

Author information

1
Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. sensass@yuhs.ac

Abstract

Pancreatic cancer is a very lethal cancer. It is the 5th most common cause for cancer related mortality in Korea. Most of patients have unresectable pancreatic cancer, and systemic chemotherapy remains the only treatment option for them. Gemcitabine has been adopted as the standard first-line agent for advanced pancreatic cancer, but the progression free survival with gemcitabine is short. Many of patients need further treatment. We reviewed the clinical trials of second line chemotherapy for gemcitabine refractory pancreatic cancer and tried to show currently available treatment options.

PMID:
21519173
DOI:
10.4166/kjg.2011.57.4.207
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Korean Society of Gastroenterology
    Loading ...
    Support Center